- Home
- PFGC vs GMAB Comparison
PFGC vs GMAB Comparison
Compare PFGC & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFGC
- GMAB
- Stock Information
- Founded
- PFGC 1885
- GMAB 1999
- Country
- PFGC United States
- GMAB Denmark
- Employees
- PFGC N/A
- GMAB N/A
- Industry
- PFGC Food Distributors
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PFGC Consumer Discretionary
- GMAB Health Care
- Exchange
- PFGC Nasdaq
- GMAB Nasdaq
- Market Cap
- PFGC 12.9B
- GMAB 13.7B
- IPO Year
- PFGC 2015
- GMAB N/A
- Fundamental
- Price
- PFGC $88.87
- GMAB $20.30
- Analyst Decision
- PFGC Strong Buy
- GMAB Buy
- Analyst Count
- PFGC 10
- GMAB 9
- Target Price
- PFGC $99.90
- GMAB $39.17
- AVG Volume (30 Days)
- PFGC 850.6K
- GMAB 1.5M
- Earning Date
- PFGC 08-13-2025
- GMAB 08-07-2025
- Dividend Yield
- PFGC N/A
- GMAB N/A
- EPS Growth
- PFGC N/A
- GMAB 276.80
- EPS
- PFGC 2.41
- GMAB 18.36
- Revenue
- PFGC $57,949,200,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- PFGC $17.92
- GMAB $747.74
- Revenue Next Year
- PFGC $5.92
- GMAB $14.81
- P/E Ratio
- PFGC $36.89
- GMAB $1.11
- Revenue Growth
- PFGC 7.20
- GMAB 25.43
- 52 Week Low
- PFGC $61.60
- GMAB $17.24
- 52 Week High
- PFGC $92.44
- GMAB $28.56
- Technical
- Relative Strength Index (RSI)
- PFGC 56.97
- GMAB 39.68
- Support Level
- PFGC $85.21
- GMAB $20.39
- Resistance Level
- PFGC $88.89
- GMAB $21.08
- Average True Range (ATR)
- PFGC 1.45
- GMAB 0.35
- MACD
- PFGC 0.05
- GMAB -0.20
- Stochastic Oscillator
- PFGC 83.00
- GMAB 2.63
About PFGC Performance Food Group Company
Performance Food Group Co is the third-largest U.S. food-service distributor behind Sysco and us Foods, with 9% market share. PFG's food-service business (52% of 2022 sales) provides customized food products and services (such as product selection and procurement) to independent and chain restaurants, and institutional customers. Acquisitions of Eby-Brown (2019) and Core-Mark (2021) enabled PFG to tap into the convenience store segment (41% of sales), offering convenience products, marketing programs, and technology solutions to convenience stores, drug stores, and other such channels. The firm's Vistar business (7% of sales) is a national distributor of candy, snacks, and beverages to vending and office coffee service distributors, theaters, and hospitality providers.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.